𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Combination chemotherapy with epirubicin, cisplatin and 5-fluorouracil for the palliation of advanced gastric and oesophageal adenocarcinoma

✍ Scribed by W. H. Allum

Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
128 KB
Volume
82
Category
Article
ISSN
0007-1323

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Paclitaxel, 5-fluorouracil, and cisplati
Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma
✍ Yeul H. Kim; Sang W. Shin; Byung S. Kim; Jin H. Kim; Jong G. Kim; Young J. Mok; πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 86 KB πŸ‘ 2 views

## Background: Although the clinical efficacy of paclitaxel in the treatment of gastric carcinoma has not been clearly defined, recent reports have suggested a possible role in the treatment of upper gastrointestinal carcinomas in vitro and in vivo. in this study, the authors evaluated the efficacy

A randomized Phase III trial of etoposid
A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma
✍ Fikri Δ°Γ§li; Δ°smail Γ‡elik; Faruk Aykan; AytuΗ§ Üner; Ahmet Demirkazik; Ahmet Γ–zet; πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 85 KB πŸ‘ 2 views

## BACKGROUND. Gastric carcinoma is a substantial health problem in Turkey, and the majority of patients present with inoperable disease. The aim of this randomized trial was to assess the activity of 5-fluorouracil versus etoposide when combined with epirubicin plus cisplatin in patients with adv

Continuous infusion of 5-fluorouracil an
Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma
✍ Yong-Suk Chung; Yoshito Yamashita; Tohru Inoue; Tasuku Matsuoka; Bunzo Nakata; N πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 85 KB πŸ‘ 2 views

City Uni-11 cases, for an overall response rate of 50%. Patients with good performance versity Medical School, Osaka, Japan. status (PS) (0-1) and differentiated histologic type showed higher response rates (50.0% and 63.6%, respectively) than patients with poor PS (2 or 3) and undifferenti-2 Insti